Molecular markers of early pancreatic cancer

被引:166
作者
Goggins, M
机构
[1] Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Med, Baltimore, MD 21205 USA
[3] Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD 21205 USA
关键词
D O I
10.1200/JCO.2005.19.711
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic cancer is a deadly disease and the fourth most common cause of cancer death in the United States. Since chemotherapy and radiotherapy have thus far largely failed to significantly improve the survival of patients with pancreatic ductal adenocarcinoma, there is considerable interest in identifying better diagnostic markers of pancreatic neoplasia. Not only could better markers improve the early diagnosis of pancreatic cancer and allow more patients to undergo curative surgical resection, but also could potentially be used for patients at high risk of developing pancreatic cancer to identify precancerous lesions while they are amenable to cure. A wealth of information has recently become available about gene expression, DNA methylation, and proteomics alterations that occur in pancreatic cancers creating hope that better diagnostic markers of pancreatic cancer will be soon forthcoming. (c) 2005 by American Society of Clinical Oncology.
引用
收藏
页码:4524 / 4531
页数:8
相关论文
共 117 条
  • [1] High-resolution characterization of the pancreatic adenocarcinoma genome
    Aguirre, AJ
    Brennan, C
    Bailey, G
    Sinha, R
    Feng, B
    Leo, C
    Zhang, YY
    Zhang, J
    Gans, JD
    Bardeesy, N
    Cauwels, C
    Cordon-Cardo, C
    Redston, MS
    DePinho, RA
    Chin, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (24) : 9067 - 9072
  • [2] AHRENDT SA, 2003, JNCI-J NATL CANCER I, V95, P981
  • [3] *AM GASTR ASS, 1999, GASTROENTEROLOGY, V117, P1463
  • [4] Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities
    Baek, SJ
    Kim, KS
    Nixon, JB
    Wilson, LC
    Eling, TE
    [J]. MOLECULAR PHARMACOLOGY, 2001, 59 (04) : 901 - 908
  • [5] Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer
    Baggerly, KA
    Morris, JS
    Edmonson, SR
    Coombes, KR
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (04): : 307 - 309
  • [6] Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments
    Baggerly, KA
    Morris, JS
    Coombes, KR
    [J]. BIOINFORMATICS, 2004, 20 (05) : 777 - U710
  • [7] Berger DH, 1999, CANCER, V85, P326, DOI 10.1002/(SICI)1097-0142(19990115)85:2<326::AID-CNCR9>3.0.CO
  • [8] 2-O
  • [9] Diagnosis of pancreatic cancer using serum proteomic profiling
    Bhattacharyya, S
    Siegel, ER
    Petersen, GM
    Chari, ST
    Suva, LJ
    Haun, RS
    [J]. NEOPLASIA, 2004, 6 (05): : 674 - 686
  • [10] MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily
    Bootcov, MR
    Bauskin, AR
    Valenzuela, SM
    Moore, AG
    Bansal, M
    He, XY
    Zhang, HP
    Donnellan, M
    Mahler, S
    Pryor, K
    Walsh, BJ
    Nicholson, RC
    Fairlie, WD
    Por, SB
    Robbins, JM
    Breit, SN
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (21) : 11514 - 11519